Indomethacin has a potent antiviral activity against SARS coronavirus.
Identifieur interne : 001E95 ( PubMed/Curation ); précédent : 001E94; suivant : 001E96Indomethacin has a potent antiviral activity against SARS coronavirus.
Auteurs : Carla Amici [Italie] ; Antonino Di Caro ; Alessandra Ciucci ; Lucia Chiappa ; Concetta Castilletti ; Vito Martella ; Nicola Decaro ; Canio Buonavoglia ; Maria R. Capobianchi ; M Gabriella SantoroSource :
- Antiviral therapy [ 1359-6535 ] ; 2006.
Descripteurs français
- KwdFr :
- ARN viral (isolement et purification), Acide acétylsalicylique (pharmacologie), Animaux, Antiviraux (pharmacologie), Antiviraux (usage thérapeutique), Chiens, Coronavirus canin (), Fèces (virologie), Humains, Indométacine (pharmacologie), Indométacine (usage thérapeutique), Infections à coronavirus (médecine vétérinaire), Infections à coronavirus (traitement médicamenteux), Interféron alpha (pharmacologie), Lignée cellulaire, Maladies des chiens (traitement médicamenteux), Relation dose-effet des médicaments, Ribavirine (pharmacologie), Réplication virale (), Virus du SRAS ().
- MESH :
- isolement et purification : ARN viral.
- médecine vétérinaire : Infections à coronavirus.
- pharmacologie : Acide acétylsalicylique, Antiviraux, Indométacine, Interféron alpha, Ribavirine.
- traitement médicamenteux : Infections à coronavirus, Maladies des chiens.
- usage thérapeutique : Antiviraux, Indométacine.
- virologie : Fèces.
- Animaux, Chiens, Coronavirus canin, Humains, Lignée cellulaire, Relation dose-effet des médicaments, Réplication virale, Virus du SRAS.
English descriptors
- KwdEn :
- Animals, Antiviral Agents (pharmacology), Antiviral Agents (therapeutic use), Aspirin (pharmacology), Cell Line, Chlorocebus aethiops, Coronavirus Infections (drug therapy), Coronavirus Infections (veterinary), Coronavirus, Canine (drug effects), Dog Diseases (drug therapy), Dogs, Dose-Response Relationship, Drug, Feces (virology), Humans, Indomethacin (pharmacology), Indomethacin (therapeutic use), Interferon-alpha (pharmacology), RNA, Viral (isolation & purification), Ribavirin (pharmacology), SARS Virus (drug effects), Virus Replication (drug effects).
- MESH :
- chemical , isolation & purification : RNA, Viral.
- chemical , pharmacology : Antiviral Agents, Aspirin, Indomethacin, Interferon-alpha, Ribavirin.
- chemical , therapeutic use : Antiviral Agents, Indomethacin.
- drug effects : Coronavirus, Canine, SARS Virus, Virus Replication.
- drug therapy : Coronavirus Infections, Dog Diseases.
- veterinary : Coronavirus Infections.
- virology : Feces.
- Animals, Cell Line, Chlorocebus aethiops, Dogs, Dose-Response Relationship, Drug, Humans.
Abstract
Severe acute respiratory syndrome (SARS) is a newly emerging, highly transmissible and fatal disease caused by a previously unknown coronavirus (SARS-CoV). Existing in non-identified animal reservoirs, SARS-CoV continues to represent a threat to humans because there is no effective specific antiviral therapy for coronavirus infections.
PubMed: 17302372
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001E95
Links to Exploration step
pubmed:17302372Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Indomethacin has a potent antiviral activity against SARS coronavirus.</title><author><name sortKey="Amici, Carla" sort="Amici, Carla" uniqKey="Amici C" first="Carla" last="Amici">Carla Amici</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biology, University of Rome Tor Vergata, Rome, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Biology, University of Rome Tor Vergata, Rome</wicri:regionArea></affiliation></author><author><name sortKey="Di Caro, Antonino" sort="Di Caro, Antonino" uniqKey="Di Caro A" first="Antonino" last="Di Caro">Antonino Di Caro</name></author><author><name sortKey="Ciucci, Alessandra" sort="Ciucci, Alessandra" uniqKey="Ciucci A" first="Alessandra" last="Ciucci">Alessandra Ciucci</name></author><author><name sortKey="Chiappa, Lucia" sort="Chiappa, Lucia" uniqKey="Chiappa L" first="Lucia" last="Chiappa">Lucia Chiappa</name></author><author><name sortKey="Castilletti, Concetta" sort="Castilletti, Concetta" uniqKey="Castilletti C" first="Concetta" last="Castilletti">Concetta Castilletti</name></author><author><name sortKey="Martella, Vito" sort="Martella, Vito" uniqKey="Martella V" first="Vito" last="Martella">Vito Martella</name></author><author><name sortKey="Decaro, Nicola" sort="Decaro, Nicola" uniqKey="Decaro N" first="Nicola" last="Decaro">Nicola Decaro</name></author><author><name sortKey="Buonavoglia, Canio" sort="Buonavoglia, Canio" uniqKey="Buonavoglia C" first="Canio" last="Buonavoglia">Canio Buonavoglia</name></author><author><name sortKey="Capobianchi, Maria R" sort="Capobianchi, Maria R" uniqKey="Capobianchi M" first="Maria R" last="Capobianchi">Maria R. Capobianchi</name></author><author><name sortKey="Santoro, M Gabriella" sort="Santoro, M Gabriella" uniqKey="Santoro M" first="M Gabriella" last="Santoro">M Gabriella Santoro</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2006">2006</date><idno type="RBID">pubmed:17302372</idno><idno type="pmid">17302372</idno><idno type="wicri:Area/PubMed/Corpus">001E95</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001E95</idno><idno type="wicri:Area/PubMed/Curation">001E95</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001E95</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Indomethacin has a potent antiviral activity against SARS coronavirus.</title><author><name sortKey="Amici, Carla" sort="Amici, Carla" uniqKey="Amici C" first="Carla" last="Amici">Carla Amici</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biology, University of Rome Tor Vergata, Rome, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Biology, University of Rome Tor Vergata, Rome</wicri:regionArea></affiliation></author><author><name sortKey="Di Caro, Antonino" sort="Di Caro, Antonino" uniqKey="Di Caro A" first="Antonino" last="Di Caro">Antonino Di Caro</name></author><author><name sortKey="Ciucci, Alessandra" sort="Ciucci, Alessandra" uniqKey="Ciucci A" first="Alessandra" last="Ciucci">Alessandra Ciucci</name></author><author><name sortKey="Chiappa, Lucia" sort="Chiappa, Lucia" uniqKey="Chiappa L" first="Lucia" last="Chiappa">Lucia Chiappa</name></author><author><name sortKey="Castilletti, Concetta" sort="Castilletti, Concetta" uniqKey="Castilletti C" first="Concetta" last="Castilletti">Concetta Castilletti</name></author><author><name sortKey="Martella, Vito" sort="Martella, Vito" uniqKey="Martella V" first="Vito" last="Martella">Vito Martella</name></author><author><name sortKey="Decaro, Nicola" sort="Decaro, Nicola" uniqKey="Decaro N" first="Nicola" last="Decaro">Nicola Decaro</name></author><author><name sortKey="Buonavoglia, Canio" sort="Buonavoglia, Canio" uniqKey="Buonavoglia C" first="Canio" last="Buonavoglia">Canio Buonavoglia</name></author><author><name sortKey="Capobianchi, Maria R" sort="Capobianchi, Maria R" uniqKey="Capobianchi M" first="Maria R" last="Capobianchi">Maria R. Capobianchi</name></author><author><name sortKey="Santoro, M Gabriella" sort="Santoro, M Gabriella" uniqKey="Santoro M" first="M Gabriella" last="Santoro">M Gabriella Santoro</name></author></analytic><series><title level="j">Antiviral therapy</title><idno type="ISSN">1359-6535</idno><imprint><date when="2006" type="published">2006</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antiviral Agents (pharmacology)</term><term>Antiviral Agents (therapeutic use)</term><term>Aspirin (pharmacology)</term><term>Cell Line</term><term>Chlorocebus aethiops</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (veterinary)</term><term>Coronavirus, Canine (drug effects)</term><term>Dog Diseases (drug therapy)</term><term>Dogs</term><term>Dose-Response Relationship, Drug</term><term>Feces (virology)</term><term>Humans</term><term>Indomethacin (pharmacology)</term><term>Indomethacin (therapeutic use)</term><term>Interferon-alpha (pharmacology)</term><term>RNA, Viral (isolation & purification)</term><term>Ribavirin (pharmacology)</term><term>SARS Virus (drug effects)</term><term>Virus Replication (drug effects)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>ARN viral (isolement et purification)</term><term>Acide acétylsalicylique (pharmacologie)</term><term>Animaux</term><term>Antiviraux (pharmacologie)</term><term>Antiviraux (usage thérapeutique)</term><term>Chiens</term><term>Coronavirus canin ()</term><term>Fèces (virologie)</term><term>Humains</term><term>Indométacine (pharmacologie)</term><term>Indométacine (usage thérapeutique)</term><term>Infections à coronavirus (médecine vétérinaire)</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Interféron alpha (pharmacologie)</term><term>Lignée cellulaire</term><term>Maladies des chiens (traitement médicamenteux)</term><term>Relation dose-effet des médicaments</term><term>Ribavirine (pharmacologie)</term><term>Réplication virale ()</term><term>Virus du SRAS ()</term></keywords><keywords scheme="MESH" type="chemical" qualifier="isolation & purification" xml:lang="en"><term>RNA, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term><term>Aspirin</term><term>Indomethacin</term><term>Interferon-alpha</term><term>Ribavirin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Indomethacin</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Coronavirus, Canine</term><term>SARS Virus</term><term>Virus Replication</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Dog Diseases</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>ARN viral</term></keywords><keywords scheme="MESH" qualifier="médecine vétérinaire" xml:lang="fr"><term>Infections à coronavirus</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Acide acétylsalicylique</term><term>Antiviraux</term><term>Indométacine</term><term>Interféron alpha</term><term>Ribavirine</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term><term>Maladies des chiens</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term><term>Indométacine</term></keywords><keywords scheme="MESH" qualifier="veterinary" xml:lang="en"><term>Coronavirus Infections</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Fèces</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Feces</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Cell Line</term><term>Chlorocebus aethiops</term><term>Dogs</term><term>Dose-Response Relationship, Drug</term><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Chiens</term><term>Coronavirus canin</term><term>Humains</term><term>Lignée cellulaire</term><term>Relation dose-effet des médicaments</term><term>Réplication virale</term><term>Virus du SRAS</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Severe acute respiratory syndrome (SARS) is a newly emerging, highly transmissible and fatal disease caused by a previously unknown coronavirus (SARS-CoV). Existing in non-identified animal reservoirs, SARS-CoV continues to represent a threat to humans because there is no effective specific antiviral therapy for coronavirus infections.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17302372</PMID><DateCompleted><Year>2007</Year><Month>03</Month><Day>16</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1359-6535</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>8</Issue><PubDate><Year>2006</Year></PubDate></JournalIssue><Title>Antiviral therapy</Title><ISOAbbreviation>Antivir. Ther. (Lond.)</ISOAbbreviation></Journal><ArticleTitle>Indomethacin has a potent antiviral activity against SARS coronavirus.</ArticleTitle><Pagination><MedlinePgn>1021-30</MedlinePgn></Pagination><Abstract><AbstractText Label="UNLABELLED">Severe acute respiratory syndrome (SARS) is a newly emerging, highly transmissible and fatal disease caused by a previously unknown coronavirus (SARS-CoV). Existing in non-identified animal reservoirs, SARS-CoV continues to represent a threat to humans because there is no effective specific antiviral therapy for coronavirus infections.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Starting from the observation that cyclopentenone cyclooxygenase (COX) metabolites are active against several RNA viruses, we investigated the effect of the COX inhibitor indomethacin on coronavirus replication.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Work involving infectious SARS-CoV was performed in biosafety level 3 facilities. SARS-CoV was grown in monkey VERO cells and human lung epithelial A549 cells, while canine coronavirus (CCoV) was grown in A72 canine cells. Antiviral activity was analysed by determining infective virus titres by TCID50, viral RNA synthesis by Northern blot analysis and real-time RT-PCR, and viral protein synthesis by SDS-PAGE analysis after 35S-methionine-labelling. Antiviral efficacy in vivo was determined by evaluating virus titres in CCoV-infected dogs treated orally with 1 mg/kg body weight indomethacin (INDO).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Unexpectedly, we found that INDO has a potent direct antiviral activity against the coronaviruses SARS-CoV and CCoV. INDO does not affect coronavirus binding or entry into host cells, but acts by blocking viral RNA synthesis at cytoprotective doses. This effect is independent of cyclooxygenase inhibition. INDO's potent antiviral activity (>1,000-fold reduction in virus yield) was confirmed in vivo in CCoV-infected dogs.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The results identify INDO as a potent inhibitor of coronavirus replication and suggest that, having both anti-inflammatory and antiviral activity, INDO could be beneficial in SARS therapy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Amici</LastName><ForeName>Carla</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biology, University of Rome Tor Vergata, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Caro</LastName><ForeName>Antonino</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Ciucci</LastName><ForeName>Alessandra</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Chiappa</LastName><ForeName>Lucia</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Castilletti</LastName><ForeName>Concetta</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Martella</LastName><ForeName>Vito</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Decaro</LastName><ForeName>Nicola</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Buonavoglia</LastName><ForeName>Canio</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Capobianchi</LastName><ForeName>Maria R</ForeName><Initials>MR</Initials></Author><Author ValidYN="Y"><LastName>Santoro</LastName><ForeName>M Gabriella</ForeName><Initials>MG</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Antivir Ther</MedlineTA><NlmUniqueID>9815705</NlmUniqueID><ISSNLinking>1359-6535</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>49717AWG6K</RegistryNumber><NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance></Chemical><Chemical><RegistryNumber>R16CO5Y76E</RegistryNumber><NameOfSubstance UI="D001241">Aspirin</NameOfSubstance></Chemical><Chemical><RegistryNumber>XXE1CET956</RegistryNumber><NameOfSubstance UI="D007213">Indomethacin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001241" MajorTopicYN="N">Aspirin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000662" MajorTopicYN="N">veterinary</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017939" MajorTopicYN="N">Coronavirus, Canine</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004283" MajorTopicYN="N">Dog Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004285" MajorTopicYN="N">Dogs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005243" MajorTopicYN="N">Feces</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007213" MajorTopicYN="N">Indomethacin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016898" MajorTopicYN="N">Interferon-alpha</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012254" MajorTopicYN="N">Ribavirin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>2</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>3</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>2</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17302372</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001E95 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001E95 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:17302372
|texte= Indomethacin has a potent antiviral activity against SARS coronavirus.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:17302372" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |